Melphalan and prednisone: An effective combination for the treatment of multiple myeloma

摘要: Abstract One hundred eighty-nine patients with multiple myeloma, previously untreated alkylating agents, were classified as "good" or "poor risk". A patient was "good risk" if he met all the following criteria: (1) blood urea nitrogen ≤ 30 mg/100 ml, (2) serum calcium 12 (3) absence of significant infection at onset study, (4) white cell count ≥ 4,000/mm 3 and platelet 100,000/mm , (5) estimated survival greater than 2 months. All other Within each risk category, randomly allocated to three treatment programs follows: A, melphalan; B, melphalan prednisone; C, melphalan, prednisone testosterone. Response defined a combination objective parameters based on changes in hemoglobin, marrow plasma cells, urinary protein, azotemia, pain performance. In good patients, pair prednisone-melphalan significantly better alone, being associated more twice rate responses (55 per cent versus 23 cent) longer (53 months months). poor same failed produce frequent response shorter (9 21